Selenium (Se) and breast cancer risk by Katarzyna Jaworska - Bieniek et al.
MEETING ABSTRACT Open Access
Selenium (Se) and breast cancer risk
Katarzyna Jaworska - Bieniek*, Anna Jakubowska, Katarzyna Durda, Tomasz Huzarski, Pablo Serrano-Fernandez,
Grzegorz Sukiennicki, Magdalena Muszyńska, Tomasz Byrski, Jacek Gronwald, Satish Gupta, Katarzyna Kaczmarek,
Jan Lubiński
From Annual Conference on Hereditary Cancers 2012
Szczecin, Poland. 30-31 August 2012
Aim of the study
The aim of the study was determination of serum Se con-
centration and identification of genetic variations in genes
related to metabolism of selenium as markers of cancer
risks for carriers of BRCA1 gene mutation and individuals
with susceptibility to unselected breast cancer.
Material and methods
Eight genotypes of 4 most common SNPs localised in
GPX1, GPX4, TXNRD2 and SEP15 were selected. Geno-
typing was performed in 27 triplets matched BRCA1
carriers (cases and controls were matched 1:2) as well as
on pairs matched 1:1 consisting of 220 unselected breast
cancer (BRCA1 excluded). Cases and controls were
matched for year of birth (+/-3 years), number and
location of cancer among Iº relatives , smoking - the
number of pack years (+/- 10%) and adnexectomy.
For group of 27 triplets matched BRCA1 carriers, all
patients were carriers of one of three Polish founder
BRCA1 mutation (C61G, 4153delA, 5382insC) and serum
was collected 1 – 2 years before tumor diagnosis. Whereas
for 220 pairs of unselected breast cancer, serum was col-
lected before treatment but during diagnosis.
The following techniques for laboratory analyses have
been applied: a) sequencing on ABI310, b) TaqMan analy-
sis (a melting-curve genotyping with fluorescence-labeled
probes based on the LightCycler 480 System (Roche
Applied Science), c) determination of selenium concentra-
tion in serum using ICP MS – inductively coupled plasma
mass spectrometry with ± 5% accuracy (Perkin Elmer).
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Table 1 Correlation between breast cancer risk and serum selenium concentration in carriers of GPX1 nCC genotype:
BRCA1 gene mutation carriers
Cancer Quartiles Concentration Se (µg/l) No. No.
cases controls
Breast (BRCA1) I 52,37 – 70,45 4 4
II 72,45 – 78,03 1 7
III 78,68 – 85,5 2 6
IV 88,5– 741,33 3 5
Unselected breast cancer
Cancer Quartiles Concentration Se (µg/l) No. No.
cases controls
Unselected breast cancer I 49,73 – 72,51 29 26
II 72,63 – 82,73 20 36
III 83,00 – 95,76 27 26
IV 96,74 – 160,97 26 30
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Results
In both studied groups there was observed that the opti-
mal concentration of selenium was in range 100 – 120µg/l
of serum independently on variants in selenoprotein cod-
ing genes.
If selenium level data were combined with some sele-
noprotein genotypes a tendency was found that the opti-
mal selenium level for carriers of GPX1 nCC genotype
(Table.1) is around 75µg/l of serum and for carriers of
GPX1 CC the optimal selenium level is 120µg/l.
Conclusions
• Selenium, depending on Se concentration, can cause
cancer or prevent against cancer.
• The effect of selenium depends on selenoprotein
genotypes and concentration of selenium in the body/
diet.
• Generally the optimal concentration of selenium for
BRCA1 mutation carriers and unselected breast cancer
is in range 100 – 120µg/l of serum.
• For women (BRCA1 mutation carriers and unse-
lected breast cancer) with genotype nCC in GPX1 gene
the optimal concentration of selenium is around 75µg/l
of serum.
• The results of association studies require confirma-
tion by a prospective observation of large groups of
patients.
• Investigation on larger number of patients are
needed especially valuable may be observations of
women with increased risk of cancers.
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